Prospective Observational Cohort Study to Describe the Use of Vectibix® in Combination With Chemotherapy in Routine Clinical Practice for Patients With Wild-type RAS Metastatic Colorectal Cancer
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Amgen
- 入组人数
- 213
- 主要终点
- Total Number of Panitumumab Infusions
研究概览
简要总结
The primary objective was to describe the pattern of use of panitumumab (Vectibix®) in combination with chemotherapy in patients with wild-type rat sarcoma viral oncogene homolog (RAS) metastatic colorectal cancer (mCRC): as first-line treatment in combination with FOLFOX or FOLFIRI or second-line treatment in combination with FOLFIRI in patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan).
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Total Number of Panitumumab Infusions
时间窗: 12 months
Percentage of Participants With at Least One Panitumumab Dose Reduction
时间窗: 12 months
Percentage of Participants With at Least One Panitumumab Dose Delay
时间窗: 12 months
Cumulative Dose of Panitumumab
时间窗: 12 months
Maximum Dose of Panitumumab
时间窗: 12 months
Duration of Exposure of All Concomitant Chemotherapy
时间窗: 12 months
Duration of exposure is the time from the first date to the last date of chemotherapy administration.
Percentage of Participants With at Least One Concomitant Chemotherapy Dose Delay
时间窗: 12 months
Duration of Panitumumab Exposure
时间窗: 12 months
Duration of exposure is the time from the first to the last panitumumab infusion
Percentage of Participants With at Least One Concomitant Chemotherapy Dose Reduction
时间窗: 12 months
Reasons for Discontinuation of Panitumumab
时间窗: 12 months
Mean Interval Between Panitumumab Infusions
时间窗: 12 months
次要结局
- Number of Participants With Resectability(12 months)
- Number of Participants With Anti-cancer Treatment After Panitumumab Discontinuation(12 months)
- Percentage of Participants With an Overall Response(12 months)
- Number of Participants With at Least One Hospitalization(12 months)
- Duration of Hospital Stay(12 months)
- Type of Post-Panitumumab Anti-cancer Treatment(12 months)
- Reasons for Hospitalization(12 months)
- Types of Hospital Visit(12 months)